See more : Tastemaker Acquisition Corp. (TMKRU) Income Statement Analysis – Financial Results
Complete financial analysis of Harsco Corporation (HSC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harsco Corporation, a leading company in the Waste Management industry within the Industrials sector.
- Heng Leasing and Capital Public Company Limited (HENG.BK) Income Statement Analysis – Financial Results
- Allot Ltd. (ALLT.TA) Income Statement Analysis – Financial Results
- Waste Connections, Inc. (WCN) Income Statement Analysis – Financial Results
- Lifecome Biochemistry Co.,Ltd. (002868.SZ) Income Statement Analysis – Financial Results
- Aerofoam Metals Inc. (AFML) Income Statement Analysis – Financial Results
Harsco Corporation (HSC)
About Harsco Corporation
Harsco Corporation provides environmental solutions for industrial and specialty waste streams worldwide. It operates through two segments, Harsco Environmental and Harsco Clean Earth. The Harsco Environmental segment offers on-site services for material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; manufactures and sells industrial abrasives, roofing granules, aluminum dross, and scrap processing systems; and produces value-added downstream products from industrial waste-stream. The Harsco Clean Earth segment provides waste management services, including transportation, specialty waste processing, and recycling and beneficial reuse solutions for hazardous wastes, and soil and dredged materials. The company was founded in 1853 and is headquartered in Camp Hill, Pennsylvania.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.07B | 1.89B | 1.85B | 1.86B | 1.50B | 1.72B | 1.61B | 1.45B | 1.72B | 2.07B | 2.90B | 3.05B | 3.30B | 3.04B | 2.99B | 3.97B | 3.69B | 3.42B | 2.77B | 2.50B | 2.12B | 1.98B | 2.11B | 2.00B | 1.72B | 1.74B | 1.63B | 1.56B | 1.50B | 1.36B | 1.42B | 1.62B | 1.94B | 1.76B | 1.35B | 1.28B | 1.17B | 1.13B | 1.26B |
Cost of Revenue | 1.63B | 1.55B | 1.49B | 1.50B | 1.14B | 1.29B | 1.22B | 1.17B | 1.36B | 1.65B | 2.23B | 2.35B | 2.57B | 2.34B | 2.25B | 2.93B | 2.69B | 2.55B | 2.10B | 1.92B | 1.60B | 1.48B | 1.59B | 1.37B | 1.20B | 1.20B | 1.11B | 1.07B | 1.04B | 961.10M | 1.03B | 1.24B | 1.59B | 1.41B | 1.10B | 1.00B | 854.50M | 825.50M | 931.10M |
Gross Profit | 435.56M | 335.73M | 357.84M | 363.05M | 359.45M | 433.64M | 386.34M | 280.76M | 366.73M | 418.95M | 662.31M | 696.50M | 732.11M | 701.80M | 738.44M | 1.04B | 1.00B | 875.71M | 666.81M | 585.68M | 514.14M | 494.97M | 514.02M | 634.95M | 521.10M | 539.40M | 514.70M | 490.00M | 452.90M | 396.60M | 390.00M | 384.90M | 355.20M | 352.00M | 246.80M | 277.10M | 314.70M | 304.80M | 330.10M |
Gross Profit Ratio | 21.05% | 17.77% | 19.36% | 19.48% | 23.90% | 25.18% | 24.04% | 19.35% | 21.28% | 20.28% | 22.87% | 22.87% | 22.17% | 23.10% | 24.69% | 26.25% | 27.19% | 25.58% | 24.11% | 23.41% | 24.27% | 25.04% | 24.38% | 31.67% | 30.28% | 31.08% | 31.63% | 31.46% | 30.28% | 29.21% | 27.42% | 23.69% | 18.28% | 20.01% | 18.27% | 21.67% | 26.92% | 26.97% | 26.17% |
Research & Development | 1.29M | 690.00K | 956.00K | 3.25M | 4.82M | 5.55M | 4.23M | 4.28M | 4.51M | 6.35M | 9.57M | 9.14M | 6.04M | 4.27M | 3.15M | 5.30M | 3.18M | 3.03M | 2.68M | 2.58M | 3.31M | 2.82M | 3.98M | 5.71M | 7.80M | 7.00M | 6.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 238.69M | 234.67M | 200.39M | 242.11M | 285.25M | 481.05M | 503.34M | 647.92M | 532.62M | 520.00M | 602.17M | 538.23M | 507.37M | 393.19M | 368.39M | 329.98M | 312.70M | 322.93M | 274.08M | 207.80M | 213.40M | 211.20M | 212.60M | 203.60M | 222.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 312.38M | 268.07M | 272.23M | 327.93M | 252.97M | 238.69M | 234.67M | 200.39M | 242.11M | 285.25M | 481.05M | 503.34M | 647.92M | 532.62M | 520.00M | 602.17M | 538.23M | 507.37M | 393.19M | 368.39M | 329.98M | 312.70M | 322.93M | 274.08M | 207.80M | 213.40M | 211.20M | 212.60M | 203.60M | 222.40M | 188.00M | 180.10M | 174.40M | 173.60M | 161.50M | 166.20M | 153.40M | 171.30M | 157.40M |
Other Expenses | 10.88M | 1.25M | 19.36M | -3.57M | -2.87M | 0.00 | 4.64M | 12.62M | 31.57M | 63.88M | 306.48M | 358.81M | -3.34M | 94.92M | -4.86M | 21.95M | -4.01M | 2.41M | 2.00M | 4.86M | 6.96M | 3.47M | 23.49M | 159.10M | 135.90M | 131.40M | 116.50M | 109.40M | 104.90M | 99.60M | 74.90M | 57.10M | 57.70M | 56.60M | 56.20M | 53.80M | 56.10M | 51.90M | 49.80M |
Operating Expenses | 324.55M | 268.76M | 273.19M | 331.18M | 257.79M | 244.24M | 238.90M | 204.67M | 246.62M | 291.60M | 490.62M | 512.48M | 650.63M | 631.81M | 518.29M | 629.41M | 537.40M | 512.80M | 397.86M | 375.83M | 340.25M | 319.00M | 350.41M | 438.89M | 351.50M | 351.80M | 333.80M | 322.00M | 308.50M | 322.00M | 262.90M | 237.20M | 232.10M | 230.20M | 217.70M | 220.00M | 209.50M | 223.20M | 207.20M |
Cost & Expenses | 1.96B | 1.82B | 1.76B | 1.83B | 1.40B | 1.53B | 1.46B | 1.38B | 1.60B | 1.94B | 2.72B | 2.86B | 3.22B | 2.97B | 2.77B | 3.56B | 3.22B | 3.06B | 2.50B | 2.29B | 1.94B | 1.80B | 1.94B | 1.81B | 1.55B | 1.55B | 1.45B | 1.39B | 1.35B | 1.28B | 1.30B | 1.48B | 1.82B | 1.64B | 1.32B | 1.22B | 1.06B | 1.05B | 1.14B |
Interest Income | 6.67M | 3.56M | 2.23M | 2.17M | 1.98M | 2.16M | 2.47M | 2.48M | 1.57M | 1.70M | 2.09M | 3.68M | 2.75M | 2.67M | 2.93M | 3.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | -103.87M | 75.16M | 63.24M | 61.61M | 44.29M | 38.15M | 47.55M | 51.58M | 46.80M | 47.11M | 49.65M | 47.38M | 48.74M | 60.62M | 62.75M | 73.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 138.96M | 163.85M | 179.04M | 159.70M | 134.88M | 132.79M | 129.94M | 141.49M | 156.48M | 176.33M | 237.04M | 272.12M | 310.44M | 315.24M | 311.53M | 337.95M | 306.41M | 252.98M | 198.07M | 184.37M | 168.94M | 155.66M | 176.53M | 159.10M | 135.90M | 131.40M | 116.50M | 109.40M | 104.90M | 99.60M | 74.90M | 57.10M | 57.70M | 56.60M | 56.20M | 53.80M | 56.10M | 51.90M | 49.80M |
EBITDA | 111.01M | 235.63M | 267.41M | 190.19M | 239.16M | 320.89M | 269.11M | 114.04M | 237.15M | 225.82M | 93.67M | 100.14M | 397.51M | 386.89M | 511.56M | 743.87M | 723.50M | 546.90M | 419.49M | 354.62M | 302.86M | 288.01M | 285.24M | 302.71M | 278.20M | 306.30M | 460.50M | 304.70M | 266.20M | 245.70M | 218.80M | 190.50M | 177.30M | 172.20M | 78.40M | 108.20M | 163.90M | 137.30M | 157.80M |
EBITDA Ratio | 5.37% | 12.47% | 14.47% | 10.20% | 15.90% | 18.63% | 16.75% | 7.86% | 13.76% | 10.93% | 3.23% | 3.29% | 12.04% | 12.73% | 17.11% | 18.75% | 19.62% | 15.98% | 15.16% | 14.17% | 14.30% | 14.57% | 13.53% | 15.10% | 16.17% | 17.65% | 28.29% | 19.56% | 17.80% | 18.10% | 15.38% | 11.72% | 9.12% | 9.79% | 5.80% | 8.46% | 14.02% | 12.15% | 12.51% |
Operating Income | 111.01M | 71.78M | 88.38M | 30.48M | 104.28M | 190.93M | 142.80M | 63.47M | 88.54M | 63.47M | -134.80M | -174.79M | 87.65M | 78.43M | 218.66M | 411.99M | 457.81M | 358.47M | 268.95M | 209.85M | 173.89M | 175.97M | 163.62M | 196.06M | 169.60M | 187.60M | 178.30M | 164.70M | 121.60M | 74.60M | 127.10M | 147.70M | 123.10M | 121.80M | 29.10M | 57.10M | 105.20M | 81.60M | 122.90M |
Operating Income Ratio | 5.37% | 3.80% | 4.78% | 1.64% | 6.93% | 11.09% | 8.89% | 4.37% | 5.14% | 3.07% | -4.65% | -5.74% | 2.65% | 2.58% | 7.31% | 10.38% | 12.41% | 10.47% | 9.72% | 8.39% | 8.21% | 8.90% | 7.76% | 9.78% | 9.86% | 10.81% | 10.96% | 10.57% | 8.13% | 5.49% | 8.94% | 9.09% | 6.34% | 6.92% | 2.15% | 4.46% | 9.00% | 7.22% | 9.74% |
Total Other Income/Expenses | -129.56M | -194.74M | -50.87M | -52.21M | -47.81M | -33.67M | -47.35M | -142.94M | -53.72M | -55.15M | -48.53M | -43.71M | -45.98M | -57.96M | -59.31M | -68.65M | 64.18M | -56.58M | -38.68M | -38.61M | -37.99M | -39.27M | -49.82M | -52.45M | -27.30M | -12.70M | -12.70M | 30.60M | 39.70M | 71.50M | 10.00M | -7.10M | -3.50M | -6.20M | -6.90M | -2.70M | 2.60M | 3.80M | -14.90M |
Income Before Tax | -18.55M | -122.96M | 37.51M | -31.13M | 56.47M | 157.25M | 95.45M | -79.47M | 34.82M | 8.32M | -183.33M | -218.50M | 41.67M | 20.48M | 159.34M | 343.34M | 382.44M | 301.89M | 230.27M | 171.24M | 135.90M | 136.70M | 113.80M | 143.61M | 142.30M | 174.90M | 165.60M | 195.30M | 161.30M | 146.10M | 137.10M | 140.60M | 119.60M | 115.60M | 22.20M | 54.40M | 107.80M | 85.40M | 108.00M |
Income Before Tax Ratio | -0.90% | -6.51% | 2.03% | -1.67% | 3.76% | 9.13% | 5.94% | -5.48% | 2.02% | 0.40% | -6.33% | -7.17% | 1.26% | 0.67% | 5.33% | 8.65% | 10.37% | 8.82% | 8.32% | 6.84% | 6.41% | 6.92% | 5.40% | 7.16% | 8.27% | 10.08% | 10.18% | 12.54% | 10.79% | 10.76% | 9.64% | 8.65% | 6.16% | 6.57% | 1.64% | 4.25% | 9.22% | 7.56% | 8.56% |
Income Tax Expense | -28.19M | 10.38M | 9.09M | -2.78M | 20.21M | 12.90M | 83.80M | 6.64M | 27.68M | 27.17M | 34.91M | 35.25M | 49.85M | 4.28M | 18.51M | 91.82M | 117.60M | 97.52M | 64.77M | 49.03M | 41.71M | 42.24M | 36.98M | 46.81M | 51.60M | 67.40M | 65.20M | 76.30M | 63.90M | 59.50M | 56.30M | 49.10M | 43.10M | 43.10M | 10.80M | 23.30M | 44.50M | 35.80M | 47.50M |
Net Income | -86.12M | -133.34M | 28.42M | -28.35M | 36.26M | 137.06M | 7.82M | -85.67M | 6.19M | -24.79M | -227.94M | -254.61M | -11.51M | 6.75M | 118.78M | 240.95M | 299.49M | 196.40M | 156.66M | 121.21M | 92.22M | 90.11M | 71.73M | 96.80M | 90.70M | 107.50M | 278.80M | 119.00M | 97.40M | 86.60M | 87.60M | 84.30M | 76.50M | 72.50M | 11.40M | 31.10M | 63.30M | 49.60M | 60.50M |
Net Income Ratio | -4.16% | -7.06% | 1.54% | -1.52% | 2.41% | 7.96% | 0.49% | -5.90% | 0.36% | -1.20% | -7.87% | -8.36% | -0.35% | 0.22% | 3.97% | 6.07% | 8.12% | 5.74% | 5.66% | 4.84% | 4.35% | 4.56% | 3.40% | 4.83% | 5.27% | 6.19% | 17.13% | 7.64% | 6.51% | 6.38% | 6.16% | 5.19% | 3.94% | 4.12% | 0.84% | 2.43% | 5.41% | 4.39% | 4.80% |
EPS | -1.08 | -1.68 | 0.36 | -0.36 | 0.46 | 1.64 | 0.10 | -1.07 | 0.08 | -0.31 | -2.82 | -3.16 | -0.14 | 0.08 | 1.48 | 2.88 | 3.56 | 2.34 | 1.88 | 1.47 | 1.13 | 1.12 | 0.90 | 1.21 | 1.11 | 1.18 | 2.86 | 0.60 | 0.96 | 0.86 | 0.88 | 0.83 | 0.73 | 0.69 | 0.11 | 0.29 | 0.58 | 0.42 | 0.51 |
EPS Diluted | -1.08 | -1.68 | 0.35 | -0.36 | 0.45 | 1.64 | 0.09 | -1.07 | 0.08 | -0.31 | -2.82 | -3.16 | -0.14 | 0.08 | 1.47 | 2.87 | 3.53 | 2.33 | 1.86 | 1.46 | 1.13 | 1.11 | 0.90 | 1.21 | 1.11 | 1.17 | 2.83 | 0.60 | 0.96 | 0.86 | 0.88 | 0.83 | 0.73 | 0.69 | 0.11 | 0.29 | 0.58 | 0.42 | 0.51 |
Weighted Avg Shares Out | 79.80M | 79.49M | 79.23M | 78.94M | 79.63M | 83.60M | 80.55M | 80.33M | 80.23M | 80.88M | 80.76M | 80.63M | 80.74M | 80.57M | 80.30M | 83.60M | 84.17M | 83.91M | 83.28M | 82.26M | 81.38M | 80.72M | 79.75M | 79.93M | 81.76M | 91.14M | 97.51M | 199.53M | 100.98M | 100.46M | 99.11M | 101.52M | 104.94M | 104.89M | 104.84M | 105.74M | 108.66M | 117.40M | 119.39M |
Weighted Avg Shares Out (Dil) | 79.80M | 79.49M | 80.29M | 78.94M | 81.38M | 83.60M | 82.84M | 80.33M | 80.37M | 80.88M | 80.76M | 80.63M | 80.99M | 80.76M | 80.59M | 84.03M | 84.72M | 84.43M | 84.16M | 83.20M | 81.95M | 81.36M | 80.13M | 80.04M | 82.03M | 91.88M | 98.34M | 199.53M | 100.98M | 100.46M | 99.11M | 101.52M | 104.94M | 104.89M | 104.84M | 105.74M | 108.66M | 117.40M | 119.39M |
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
Panagora Asset Management Inc. Invests $3.12 Million in Enviri Co. (NYSE:NVRI)
Harsco changes name to Enviri, to trade on ticker ‘NVRI'
Are Business Services Stocks Lagging Crawford & Company (CRD.A) This Year?
Despite Fast-paced Momentum, Harsco (HSC) Is Still a Bargain Stock
Does Harsco (HSC) Have the Potential to Rally 25.78% as Wall Street Analysts Expect?
Harsco Corporation: Investing In A Greener Future
Harsco Corporation (HSC) Q1 2023 Earnings Call Transcript
Harsco (HSC) Reports Q1 Loss, Tops Revenue Estimates
Harsco Corporation Announces Timing of First Quarter 2023 Results and Conference Call
Source: https://incomestatements.info
Category: Stock Reports